Predicting the risk of coronary heart disease. II: the role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction.
This is the second of two articles reviewing recent findings about the risk of coronary heart disease. This paper is concerned with novel molecular biomarkers, genetic markers of risk and the future of risk prediction.
Dent
T H S
TH
PHG Foundation, 2 Worts Causeway, Cambridge CB1 8RN, United Kingdom. tomdent07@yahoo.co.uk
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001057:Apolipoproteins E; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis; D003327:Coronary Disease / Q000209:etiology* / Q000235:genetics; D055316:Cystatin C / Q000097:blood; D005340:Fibrinogen / Q000032:analysis; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood; D012306:Risk; D018570:Risk Assessment; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D015415:Biomarkers; D055316:Cystatin C; D008074:Lipoproteins; D006710:Homocysteine; D020097:Natriuretic Peptide, Brain; D014527:Uric Acid; D005340:Fibrinogen; D002097:C-Reactive Protein; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase